Program
experimental vaccine
Also written as “Low-dose experimental vaccine”, “High-dose experimental vaccine” and “Experimental vaccine”.
Its studies are mostly in Meningitis, Meningococcal · Herpes Zoster · Poliomyelitis · Hand, Foot and Mouth Disease, led by Sinovac Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 75 open or running | phase 4since May 25, 2022 | May 18, 2022 | Nov 2026phase 3 · NCT07505888 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2022First study: phase 3 study in PoliomyelitisFirst studyNCT05386810 · 1,572 enrolled · China
- May 25, 2022Phase 4 study in Hand, Foot and Mouth DiseaseNCT05397587 · 474 enrolled · China
- Jan 26, 2026Phase 2 study in Herpes ZosterNCT07400003 · 519 planned · China
- Mar 13, 20264 phase 3 studies in Meningitis, MeningococcalNCT07505888, NCT07505836, NCT07505823 and 1 more
Ahead
- Nov 2026Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505888
- Jan 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505836
- Apr 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505823
- Apr 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505810
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“experimental vaccine”name, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07505888Meningitis, Meningococcal · China | 3 | Active, not recruiting | Nov 2026 | 660 |
| NCT07505836Meningitis, Meningococcal · China | 3 | Recruiting | Jan 2027 | 1,040 |
| NCT07505823Meningitis, Meningococcal · China | 3 | Recruiting | Apr 2027 | 1,040 |
| NCT07505810Meningitis, Meningococcal · China | 3 | Recruiting | Apr 2027 | 880 |
| NCT07400003Herpes Zoster · China | 2 | Recruiting | May 31, 2026 | 519 |
| NCT05397587Hand, Foot and Mouth Disease · China | 4 | UNKNOWN | Jul 30, 2025 | 474 |
| NCT05386810Poliomyelitis · China | 3 | Completed | Oct 8, 2022 | 1,572 |
How it is read
Names in the registry
- “experimental vaccine”, 4 entries
- “Low-dose experimental vaccine”, 1 entry
- “High-dose experimental vaccine”, 1 entry
- “Experimental vaccine”, 1 entry
- “Experimental Vaccine”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Meningococcal, 4 studies
- Herpes Zoster, 1 study
- Poliomyelitis, 1 study
- Hand, Foot and Mouth Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.